These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38280086)

  • 1. Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study.
    Fernandes M; Placidi F; Mercuri NB; Liguori C
    Neurol Sci; 2024 Jul; 45(7):3443-3448. PubMed ID: 38280086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
    Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
    Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
    Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
    CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
    Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
    Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
    Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.
    Zammit G; Dauvilliers Y; Pain S; Sebök Kinter D; Mansour Y; Kunz D
    Neurology; 2020 May; 94(21):e2222-e2232. PubMed ID: 32341187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials.
    Jiang F; Li H; Chen Y; Lu H; Ni J; Chen G
    Medicine (Baltimore); 2023 Feb; 102(7):e32754. PubMed ID: 36800596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
    Ziemichód W; Grabowska K; Kurowska A; Biała G
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
    Roch C; Bergamini G; Steiner MA; Clozel M
    Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis.
    Dutta S; Singhal S; Shah R; Charan J; Dhingra S; Haque M
    Expert Opin Drug Saf; 2023; 22(12):1237-1251. PubMed ID: 37526060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.
    Boof ML; Dingemanse J; Brunke M; Esselmann A; Heymer P; Kestermann O; Lederer K; Fietze I; Ufer M
    J Sleep Res; 2021 Aug; 30(4):e13248. PubMed ID: 33417730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daridorexant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(5):601-607. PubMed ID: 35298826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia.
    Najib J; Toderika Y; Dima L
    Am J Ther; 2023 Jul-Aug 01; 30(4):e360-e368. PubMed ID: 37449930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia.
    Park J; Render PharmD KP; Cates PharmD DW
    Ann Pharmacother; 2023 Sep; 57(9):1076-1087. PubMed ID: 36602018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism of the dual orexin receptor antagonist daridorexant.
    Treiber A; Delahaye S; Weigel A; Aeänismaa P; Gatfield J; Seeland S
    Xenobiotica; 2023 Mar; 53(3):173-183. PubMed ID: 36809238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in the Treatment of Insomnia.
    Chakraborty DS; Choudhury S; Lahiry S
    Curr Drug Res Rev; 2023; 15(2):149-158. PubMed ID: 36366844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats.
    Steiner MA; Toeroek-Schafroth M; Giusepponi ME; Dacome L; Tessari M
    J Psychopharmacol; 2023 Dec; 37(12):1249-1260. PubMed ID: 38059356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.